2.1100 -0.15 (-6.64%)
After hours: 7:59PM EDT
|Bid||2.1100 x 2200|
|Ask||2.1500 x 4000|
|Day's range||2.0100 - 2.3500|
|52-week range||0.3200 - 5.6400|
|Beta (5Y monthly)||2.05|
|PE ratio (TTM)||N/A|
|Earnings date||11 Nov 2020 - 16 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.83|
BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ (www.littlegrapevine.com) beginning today, May 29, 2020, at 10:30 a.m. Eastern Standard Time. Accompanying the presentation will be a short executive introduction, as well as a brief Q&A with Mr. Goldberger. No fee is required to join or view the company’s Little Grapevine Conference presentation, as it is open to the public.
electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -4.00% and 0.55%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced first quarter 2020 financial results and provided an operational update. Received 510(k) clearance from FDA to expand the gammaCore label into migraine prevention. Announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore (nVNS) in the treatment of cluster headache in adults, through September 2020.